Accepted at 8:26 p.m. Apr, 03, 2024 by herstein.jacob
Author: Cameron
Related Note: 1476496102004 1
Rationale for change

QID is directly asking what is causing myelosuppression in this patient taking hydroxyurea. Knowing MOA of hydroxyurea is necessary to answer as the correct answer choice is "Medication-induced inhibition of NA synthesis enzyme"

Text
{{c1::Hydroxyurea}} inhibits {{c2::ribonucleotide reductase}}, which normally catalyzes conversion of UDP to dUDP (pyrimidine synthesis)
Extra

Image licensed by Physeo and used with permission. Purchase full access here.
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid

Sketchy

Watch Purine (De Novo) & Pyrimidine Synthesis
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize

Review De Novo Pyrimidine Synthesis
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - DNA Structure : Clinical Applications of the Pyrimidine Pathway

Watch associated Bootcamp video - Plasma Cell Dyscrasias and Myeloproliferative Disease: Polycythemia Vera and Essential Thrombocythemia

Watch associated Bootcamp video - Principles of Oncology and Therapeutics: Cell Cycle Dependent Drug Targets
OME

Additional Resources
One by one
Empty field
Changed Tags
#AK_Step1_v12::#UWorld::19689
#AK_Step1_v12::#OME::PreClinical::Biochemistry #AK_Step1_v12::#B&B::03_Biochem::01_Molecular::03_Pyrimidine_Metabolism #AK_Step1_v12::#Physeo::05_Biochem::05_Metabolism::18_Purines_&_Pyrimidines !AK_UpdateTags::Step1decks::Zanki-Step-Decks::Zanki-Biochemistry::Metabolism #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::03_Polycythemia_Vera_&_Essential_Thrombocythemia #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Biochemistry::Metabolism #AK_Step1_v12::#FirstAid::01_Biochem::01_Molecular::03_De_novo_pyrimidine_and_purine_synthesis::01_Pyrimidine_synthesis::*Hydroxyurea #AK_Step1_v12::#Bootcamp::Genetics::01_DNA_Structure::05_Clinical_Applications_of_the_Pyrimidine_Pathway #AK_Step1_v12::#FirstAid::01_Biochem::01_Molecular::03_De_novo_pyrimidine_and_purine_synthesis #AK_Step1_v12::#B&B::11_Hematology::04_Cancer_Drugs::01_Antimetabolites #AK_Step1_v12::#UWorld::Step::19689 #AK_Step1_v12::#UWorld::COMLEX::27183 #AK_Step1_v12::^Systems::Biochem::metabolism::protein #AK_Step1_v12::#SketchyBiochem::03_Molecular_Biology::01_DNA::05_Purine_(De-Novo)_Pyrimidine_Synthesis #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#FirstAid::01_Biochem::01_Molecular::03_De_novo_pyrimidine_and_purine_synthesis::01_Pyrimidine_synthesis::*Pyrimidine_Metabolism #AK_Step1_v12::#Pixorize::01_Biochemistry::02_Biochemical_Pathways::06_De_Novo_Pyrimidine_Synthesis